Skip to main
HSCS

HSCS Stock Forecast & Price Target

HSCS Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartSciences Inc is experiencing a positive financial trajectory, as evidenced by upward adjustments to its fiscal year 2026 earnings per share (EPS) estimates, suggesting improved operational performance amidst a growing share count. The anticipated approval of the MyoVista device, along with the rollout of the MyoVista Insights cloud platform and expected FDA approval for its first diagnostic algorithm in the first half of 2026, positions the company strategically for significant expansion in the cardiac diagnostic market. Furthermore, the new price target of $9.20 indicates a robust upside potential, reflecting a favorable net present value analysis that underscores HeartSciences's promising growth prospects.

Bears say

HeartSciences Inc. is currently facing significant challenges that contribute to a negative outlook on its stock, particularly highlighted by a drastic reduction in the FY2026 revenue estimate from $1.2 million to $0.1 million due to FDA-related delays. Additionally, the company is exposed to multiple risks, including balance sheet and liquidity concerns, potential failures in clinical trials, difficulties in gaining regulatory approvals, and competition within the healthcare sector. Overall, these factors, compounded by shifts in investor sentiment and healthcare priorities, significantly impact the company's financial outlook and operational viability.

HSCS has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Heart Test Laboratories Inc (HSCS) Forecast

Analysts have given HSCS a Strong Buy based on their latest research and market trends.

According to 1 analysts, HSCS has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Heart Test Laboratories Inc (HSCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.